2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2369

Relationship of Bone Mineral Density and Inflammatory Burden with Carotid Plaque Formation in Rheumatoid Arthritis: A 5-Year Prospective Study
Abstract Number: 2370

Endothelial Nitric Oxide Synthase Gene Polymorphism As a Risk Factor of Hypertension in Patients with Rheumatoid Arthritis
Abstract Number: 2371

The Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis Stratified By Baseline Body Mass Index
Abstract Number: 2372

Obesity and the Impact on Treat to Target Goals and Functional Ability in RA. Results from Two Multi-Centre UK Inception Cohorts
Abstract Number: 2373

Low or High BMI Negatively Impacts RA Disease Activity in an Asian RA Cohort
Abstract Number: 2374

Obesity Impacts ESR and Not Other Measures of Rheumatoid Arthritis Disease Activity
Abstract Number: 2375

Does the Body Mass Index Have Any Influence in the Characteristics of Early Arthritis Patients?
Abstract Number: 2376

Weight Histories Expose the Systematic Underestimation of the Risks of Obesity on Mortality in Rheumatoid Arthritis
Abstract Number: 2377

Impact of Body Mass Index and Weight Loss on Incident Disability in Patients with Rheumatoid Arthritis
Abstract Number: 2378

Body Mass Index and Persistence of Conventional Dmards and TNF Inhibitors in Rheumatoid Arthritis
Abstract Number: 2379

Effect of DKK-1 and Osteoprotegerin on Bone Mass in Tightly Controlled Rheumatoid Arthritis
Abstract Number: 2380

The Use of Fibroscan in Detecting Early Liver Fibrosis in RA Patients on Long Term MTX with Normal Liver Enzymes
Abstract Number: 2381

Hematologic Abnormalities during the Use of Low Dose Methotrexate for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: 2382

Reliability of the Biochemical Bone Markers CTX and P1NP during a TNF-Inhibitor Treatment Cycle in Patients with Rheumatoid Arthritis
Abstract Number: 2383

Frailty and Risk of Fractures in Patients with Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].